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PCOS is one of the most common endocrine disorders and NAFLD is one of its most
dangerous metabolic consequences. The diagnosis of NAFLD is not a practical task and
the condition is at risk of being overlooked. The use of simpler but still reliable surrogate
markers is necessary to identify women with a high likelihood of NAFLD. The aim of this
study was to evaluate the clinical correlates of NAFLD Liver Fat Score (NAFLD-LFS) in
women with oligomenorrhea and/or hirsutism. Furthermore, the study aimed to evaluate
whether, among the hormonal parameters evaluated in such women, possible hallmarks
of NAFLD may be identified. To this purpose, 66 women who attended our Outpatient
Clinic for oligomenorrhea and/or hyperandrogenism were included in the study. In order to
validate the results obtained in the first cohort, a second independent sample of 233
women evaluated for female sexual dysfunction (FSD) was analyzed. In cohort 1, NAFLD-
LFS positively correlated with metabolic and inflammatory parameters. Among the
hormone parameters, NAFLD-LFS showed no significant relationships with androgens
but a significant negative correlation with SHBG (p<0.0001) that therefore appeared as a
candidate hallmark for pathologic NAFLD-LFS. The ROC analysis showed a significant
accuracy (81.1%, C.I.69.1-93.0, p <0.0001) for SHBG in identifying women with a
pathological NAFLD-LFS. In particular, a SHBG 33.4 nmol/l was recognized as the best
threshold, with a sensitivity of 73.3% and a specificity of 70.7%. In order to validate this
SHBG as a marker of metabolic impairment possible related with the presence of NAFLD,
we tested this threshold in cohort 2. FSD women with SHBG <33.4 nmol/l had worse
metabolic parameters than women with SHBG ≥33.4 nmol/l and a significantly higher
NAFLD-LFS even after adjusting for confounders (B=4.18 [2.05; 6.31], p=0.001). In
conclusion, this study provides a new evidence in the diagnostic process of NAFLD,n.org March 2021 | Volume 12 | Article 6414461
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Frontiers in Endocrinology | www.frontiersishowing that the measurement of SHBG, which is routinely assessed in the workup of
women referred for possible PCOS, could identify women at higher metabolic risk, thus
detecting those who may deserve further targeted diagnostic assessment.Keywords: sex hormone binding globulin (SHBG), non-alcoholic fatty liver disease (NAFLD), polycystic ovary
syndrome (PCOS), metabolic syndrome, female sexual dysfunctionINTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is characterized by a
spectrum of disorders ranging from the simple fatty liver to non-
alcoholic steatohepatitis (NASH), with increasing fibrosis leading
to cirrhosis (1–4). Nowadays, NAFLD is considered the hepatic
hallmark of insulin resistance in several metabolic disorders.
Hence, recognizing NAFLD may be of pivotal importance
because it increased the risk of developing not only hepatic but
also extrahepatic diseases, such as cardiovascular disease (CVD),
chronic kidney disease (CKD) and type 2 diabetes mellitus
(T2DM) (5–7). Growing evidence indicates a high prevalence
of NAFLD in women with polycystic ovary syndrome (PCOS).
In fact, in PCOS, NAFLD ranges from 34% to 70% as compared
with a 14–34% in the female general population (8–15). This
emerging association between NAFLD and PCOS was
substantiated by evidence of common pathogenic mechanisms
between the two conditions (16, 17). Recent studies confirmed
that both insulin resistance and hyperandrogenism are key
players of liver damage in women with PCOS, with a major
role of the second one in non-obese patients (18, 19). PCOS, one
of the most common endocrine disorders, affects 5-10% of
reproductive-aged women (20), presenting not only a
reproductive, but also an oncological and a cardio-metabolic
burden. Among these, NAFLD is often overlooked. Therefore,
due to this high frequency and its key consequences, the
evaluation of hepatic health should be mandatory in patients with
PCOS. However, the diagnosis of NAFLD is not an easy task. Liver
biopsy remains the gold standard; however, it may not be
considered the first line procedure in a prevalent condition such
as PCOS. Therefore, the use of simpler, but still reliable, surrogate
markers is necessary to identify women with a high likelihood of
NAFLD. To this purpose, several algorithms, based on clinical and
biochemical easily available information, have been introduced (21,
22). The best-validated steatosis algorithms are the SteatoTest®, the
Fatty Liver Index (FLI) and the NAFLD Liver Fat Score. All these
algorithms have been validated in the general population or in
severe obese populations and variably predict hepatic and cardio-
metabolic outcomes/mortality (21, 23).
In the last years, the FLI and the NAFLD –LFS algorithms
were applied in large cohorts of patients showing great accuracy
as markers of liver damage, in particular in metabolically
susceptible populations (13, 24–26). In addition, a very recent
study, comparing four non-invasive NAFLD score, i.e. FLI,
NAFLD-LFS, Hepatic Steatosis Index (HIS) and Lipid
Accumulation Product (LAP), concluded that, whereas FLI is
the most accurate in a population-based setting, NAFLD- LFS
performs better in the high-risk subjects (27).n.org 2The aim of the present study was to evaluate the clinical and
biochemical correlates of NAFLD-LFS in women who refer to an
outpatient endocrinology clinic for oligomenorrhea and/or
hirsutism and thus undergoing further investigations for PCOS
diagnosis. Furthermore, since NAFLD-LFS is more convenient
than liver biopsy but still impractical for routine clinical practice,
the study aimed to evaluate whether, among the hormonal
parameters, routinely used for the diagnostic workup of PCOS,
there are any that better predicts a pathological NAFLD-LFS.
Essentially, we found that sex hormone binding globulin (SHBG)
below 33.4 nmol/l was able to predict a high risk for NAFLD in
women consulting for PCOS, thus suggesting it as a possible
biochemical hallmark of this hepatic disease. Therefore, in the
second part of the study we tested this cut-off in a larger cohort of
women referring to our Unit for PCOS-unrelated reasons, such
as sexual difficulties.MATERIALS AND METHODS
Study Design
This study was designed as a cross-sectional prospective study
including two cohorts of women attending our outpatient clinics.
Data were retrospectively collected by revising the medical records.
Patients’ Recruitment (Cohort 1
and Cohort 2)
The first cohort of this study included a consecutive series of 66
women who attended the Andrology, Women’s Endocrinology and
Gender Incongruence Outpatient Clinic at the University of Florence
(Florence, Italy) seeking medical care for oligomenorrhea and/or
clinical hyperandrogenism and, therefore, evaluated for possible
PCOS. The study protocol was in accordance with the Declaration
of Helsinki andwas approved by the local ethics committee (protocol
PCOSFLOWMETS-12/811 OSS, Careggi Hospital, Florence, Italy).
Informed consent was obtained before the initiation of any clinical
procedures (a parent’s consent was obtained for underage patients).
PCOS was diagnosed according to the Rotterdam Criteria (28, 29).
Exclusion criteria were the differential diagnosis of PCOS (thyroid
diseases, hyperprolactinemia, non-classical congenital adrenal
hyperplasia, acromegaly and Cushing disease), uncontrolled
psychiatric disorders and inability to provide study consent. At the
first visit, demographic and clinical data were collected as part of
routine practice, including information on menstrual cycle, sexual
life, habit to perform physical activity, medications used and
associated medical conditions. “Physical activity” is a dichotomous
variable (yes/no) in which “yes” indicates that the patients performed
physical activity (of any kind) and “no” indicates that the patients didMarch 2021 | Volume 12 | Article 641446
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week” is a categorical variable including 4 levels: No physical activity
- 1-3 hours/week - 4-6 hours/week - more than 7 hours for week.
Patients also underwent a physical examination with measurement
of body weight, height, body mass index (BMI), waist circumference,
bioimpedance analysis, systolic and diastolic blood pressure.
Hirsutism was evaluated using the modified Ferriman Gallwey
(mFG) Score (30). Hirsutism was defined by a mFG score ≥ 8 for
caucasian women (100% of the analytical sample). Polycystic
Ovarian Morphology (PCOM) was defined according to the
criteria of Androgen Excess and Polycystic Ovary Syndrome Society
(31). Specifically, new ultrasound machines (transducers with
frequencies ≥8 mHz) allow diagnosis of PCOM in patients having
at least 20 small follicles (2 to 9 mm) in the whole ovary while
ovarian size at 10 mL remains the threshold for the definition of
increased ovary size (preferred criterion when using transducer
frequencies <8 mHz) (31, 32).
In order to validate the results obtained in the first cohort, a
second independent sample was analyzed (Cohort 2). Cohort 2
included 233 consecutive patients who attended the Andrology,
Women’s Endocrinology and Gender Incongruence Outpatient
Clinic seeking medical care for female sexual dysfunction (FSD).
These women did not take drugs that could alter SHBG levels,
such as antiepileptics and estroprogestins. Informed consent was
obtained before the initiation of any clinical procedures.
Exclusion criteria were history of drug or alcohol abuse and a
diagnosis of uncontrolled or unstable disease. At the first visit,
demographic and clinical data were collected as part of routine
practice, including information on menopause, medications
used, and associated medical conditions. Previous diagnoses of
mental disorders were assessed using the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition criteria
(33). Patients also underwent a physical examination
with measurement of body weight, height, BMI, waist
circumference, bioimpedance analysis, systolic and diastolic
blood pressure. The assessment of NAFLD-LFS was possible in
26 patients (11.2% of total cohort). All patients underwent
metabolic assessment and a Color Doppler Ultrasound (CDU)
examination of clitoral vascularization.
Biochemical Parameters
In patients from both the cohorts, blood samples were drawn in the
morning after an overnight fast in early follicular phase (in pre-
menopausal women) for the measurement of metabolic and
hormonal parameters. Among the metabolic parameters we
measured: blood glucose (using the glucose hexokinase method;
Dimension Vista 1500, Siemens Medical Solutions USA, Malvern,
PA, USA), total cholesterol, high-density lipoprotein cholesterol,
and triglycerides (using the automated enzymatic colorimetric
method; Dimension Vista 1500), insulin levels (using an electro-
chemiluminescence immunoassay; Roche Diagnostics, Mannheim,
Germany), glycated hemoglobin levels (using high-performance
liquid chromatography; Variant II, Biorad Laboratories, Hercules,
CA, USA), AST and ALT (COBAS 8000, Roche). Low-density
lipoprotein (LDL) cholesterol was estimated indirectly by the
Friedewald formula, unless triglycerides were >400 mg/dl (34).Frontiers in Endocrinology | www.frontiersin.org 3In addition, the following hormones were measured: LH,
Follicle- Stimulating Hormone (FSH), Estradiol (E), prolactin,
thyroid stimulating hormone (TSH), FT3, FT4 (using the
chemiluminescence method; DIMENSION VISTA ® System,
Siemens), testosterone (using the chemiluminescence method;
CENTAUR, Siemens), 17 alpha-OH-progesterone (using the
RadioImmunoAssay method; DIASOURCE, Belgium), delta 4-
androstenedione (using RadioImmunoAssay method;
BECKMAN COULTER), dehydroepiandrosterone sulfate,
DHEAS (using the electro-chemiluminescence immunoassay;
COBAS, ROCHE, Germany), SHBG (using the electro-
chemiluminescence immunoassay; COBAS, ROCHE,
Germany) and anti-Mullerian hormone, AMH (using the
chemiluminescence method; BECKMAN COULTER). Free
androgen index (FAI) was calculated as the total testosterone
to SHBG ratio and then multiplied by 100. HOMA IR was
calculated as (fasting plasma glucose*insulin/405) where glucose
was expressed in mg/dl and insulin in mU/L (35).
Non-Alcoholic Fatty Liver Disease
Assessment
The risk of being affected by NAFLD was estimated by the
NAFLD Liver Fat Score (NAFLD-LFS) (36), according to the
following formula:
NAFLD-LFS: -2.89 + 1.18 * metabolic syndrome (yes = 1/no =
0) + 0.45* type 2 diabetes (yes =2/no=0) + 0.15 * insulin (mU/L) +
0.04 *AST (U/L) - 0.94 * AST/ALT
Metabolic syndrome (MetS) was defined according to criteria
of the International Diabetes Federation (IDF) (37). In addition,
the IDF adult criteria can be used for adolescents aged ≥ 16 years,
while a modified version of these criteria can be applied to those
aged 10 to < 16 years (use 90th percentile cutoff point for waist
and < 40 mg/dl of HDL) (38).
NAFLD-LFS above -0.640 predicted NAFLD with sensitivity
of 86% and specificity of 71% (36).
Other possible causes of liver steatosis were ruled out by
history taking.
Color Doppler Ultrasound Assessment
As for clinical practice, CDU was performed only in cohort 2 by
an experienced operator blinded to the clinical data using the
MyLabClass-C sonography system (Esaote SpA, Genova, Italy); a
linear transducer (LA523, 6e13 MHz) was used. All women were
scanned in a quiet room with consistent conditions of heating
and lighting to decrease the impact of external factors on blood
flow. For premenopausal women, CDU was carried out during
the early follicular phase of the menstrual cycle (days 3-5). CDU
was performed according to a previously published operating
procedure (39–50). Briefly, the exam was performed after 12
hours of sexual abstention (sexual intercourse or masturbation),
and immediately after bladder voiding. Patients were scanned in
the lithotomy position, with a good quantity of sonographic jelly
to avoid interference from air and without applying any
significant pressure on the genital tissues, to minimize possible
artifacts (51, 52). A cross-section of the clitoris was obtained by
placing the probe transversally at the top of the vulva; this planeMarch 2021 | Volume 12 | Article 641446
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appear well defined at the center of each clitoral body (51, 52).
When adequate Doppler signals were detected, pulse-wave
Doppler mode was activated and blood flow velocity
waveforms were recorded, with automatic computation of the
PI. The PI represents the difference between the peak systolic and
the end-diastolic flows divided by the mean maximum flow
velocity (53). Because it characterizes the shape of the spectral
waveform, it is independent of the probe angle to the vessel (54).
At least three similar sequential waveforms were sampled for
each cavernous artery to define a mean PI value.
Statistical Analysis
Data were expressed as mean ± SD when normally distributed
and as median (quartile) for parameters with non-normal
distribution, unless otherwise specified. Furthermore,
categorical variables were reported as number and percentage.
Correlations were assessed using the Spearman method.
Significant correlations at univariate analysis were tested at
multivariate analysis after adjusting for confounding factors.
Linear regression was applied for multivariate analysis. ROC
curve analysis was used for the evaluation of the accuracy of
SHBG in detecting the risk to have NAFLD, and the coordinates
of the ROC curve have been evaluated for the identification of a
possible threshold value. All statistical analyses were performed
using SPSS 26.0 for Windows (SPSS Inc, Chicago, IL, USA).RESULTS
Table 1 lists the main characteristics of the two samples and the
comparisons for the available variables. In the first cohort, 55 out
of 66 patients were diagnosed with PCOS (according Rotterdam
criteria). Nine patients were diagnosed such as “not PCOS” (i.e.
only oligomenorrhea or hyperandrogenism) and two patients
had not a definitive diagnosis, at the time of the study analysis. At
univariate analysis, NAFLD-LFS was positively correlated with
BMI, waist circumference, fasting plasma glucose (FPG), insulin,
glycated hemoglobin, HOMA index, HDL cholesterol,
triglycerides, blood pressure (SBP and DBP), fat mass (FM),
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
white blood cells (WBC) and FAI. Conversely, NAFLD-LFS
negatively correlated with the time spent weekly for physical
activity. Accordingly, women reporting regular physical activity
had significantly lower NAFLD-LFS than physically inactive
women did (-0.74 vs.-1.80 p=0.015). Among the hormone
parameters, NAFLD-LFS showed a significant negative
correlation only with SHBG, while there were no correlations
between NAFLD-LFS with testosterone and other androgens
(Table 2). Considering that the NAFLD-LFS algorithm includes,
among its factors, waist circumference, SBP and DBP and that
BMI largely overlaps with waist circumference measurement,
SHBG was then identified as the candidate hallmark for
pathologic NAFLD-LFS.
A ROC curve analysis (Figure 1) was performed and showed
that SHBG has an accuracy of 81.1% (69.1-93.0, p <0.0001) inFrontiers in Endocrinology | www.frontiersin.org 4identifying women with a pathological NAFLD-LFS. In
particular, a value of 33.4 nmol/l was found to be the best cut-
off, with a sensitivity of 73.3% and a specificity of 70.7%. Using
this threshold, the probability of having a pathological NAFLD-
LFS score in women with SHBG <33.4 or >= 33.4 nmol/L was
47.8% and 12.1%, respectively (p=0.003). Subsequently, patients
were categorized according to this SHBG threshold and the
differences between patients with SHBG above or below 33.4
nmol/L in metabolic, hormonal and ultrasound parameters were
evaluated (Figure 2 and Supplementary Table 1). At univariate
analysis, values of SHBG<33.4 nmol/l were positively associated
with several cardio-metabolic risk factors [SBP, DBP, BMI, waist
circumference, (FM), Free Fat Mass (FFM), insulin, HOMA
index and triglycerides], and with androstenedione. Figure 2
also reports the clear-cut and obvious association between SHBG
and FAI, a parameter resulting from the TT to SHBG ratio. On
the contrary, a negative association was found between SHBG
and HDL cholesterol levels.
In order to further validate the identified SHBG cut-off, we
retested the above-mentioned relationships in an independent
cohort of women seeking medical care for FSD at the same
outpatient clinic (cohort 2).
Table 1 also lists the main characteristics of this second
cohort and the comparison with the cohort # 1.
At univariate analysis (Figure 3 and Supplementary Table
2), women with SHBG <33.4 nmol/l had significantly higher
BMI, waist circumference, fasting blood glucose, insulin, glycated
hemoglobin, HOMA index, triglycerides, prolactin, FAI and
lower HDL cholesterol. After adjusting for age and waist
circumference, the associations among insulin, HOMA index,
triglycerides, HDL cholesterol and FAI still retained statistical
significance. In addition, also the association between SHBG
levels and waist circumference retained significance, in an age-
adjusted model. Women with SHBG <33.4 nmol/l had also a
significantly higher NAFLD-LFS, both in unadjusted and
adjusted models (p<0.0001 and p=0.001, respectively – data
shown in Supplementary Tables).
In this second cohort, the association between SHBG values
and clitoral ultrasound parameters was also evaluated (Figure 4).
We observed a higher clitoral pulsatility index in women with
SHBG < 33.4 nmol/l, even though a full statistical significance
was not achieved.
In order to assess which SHBG value may be considered as
“normal”, women from cohort #2 of childbearing age and not
affected by MetS (n = 86) were selected. In this population, the
median SHBG value was 71.55 nmol/l with 90% of the population
ranging from 39.2 to 166.7 nmol/L. Therefore, the value of 33.4
nmol/l, identified in women with hyperandrogenism and/or
oligomenorrhea, may be considered below normality for healthy
women of childbearing age.DISCUSSION
The present study confirms the correlation between NAFLD
and metabolic parameters in a cohort of patients withMarch 2021 | Volume 12 | Article 641446
Di Stasi et al. SHBG predicts NAFLD in Womenoligomenorrhea and/or hirsutism and identify a cut-off of SHBG
able to predict the risk of NAFLD in this population. Young
women with SHBG below 33.4 nmol/L showed a higher
probability of having pathological NAFLD-LFS score as
compared to those with SHBG above this value. In an
independent population of patients seeking medical care for
sexual dysfunction, this cut-off was also able to discriminate
women at higher cardio-metabolic risk. By analyzing in the first
cohort the correlations between the NAFLD-LFS and several
parameters, positive correlations were found with blood
pressure, glyco-lipidic parameters, inflammatory indices, waist
circumference and BMI, while a negative correlation was found
with SHBG. The latter result confirms previously reported data,
which identify SHBG as an indicator of liver metabolic
impairment (55).Frontiers in Endocrinology | www.frontiersin.org 5SHBG is a glycoprotein produced by the liver and it is
involved in the transport of sex hormones in the bloodstream,
having a major role in the regulation of their circulating free
levels. Interestingly, this protein is increasingly recognized as a
hepatokine and is involved in the occurrence and development of
metabolic disorders and of their cardiovascular consequences
(56, 57).
So far, the relationship between SHBG and NAFLD in
patients with PCOS has been evaluated in a single retrospective
study. As compared with age- and BMI-matched control women,
PCOS patients had higher serum testosterone and reduced
SHBG levels, being both associated with an increased NAFLD
hazard (58). Interestingly, this study also showed that SHBG <30
nmol/L was associated with five-fold higher NAFLD risk than
SHBG >60 nmol/L (58). This previous finding corroborates ourTABLE 1 | Characteristics of the two samples.
Cohort 1 (66 women with oligomenorrhea
and/or hyperandrogenism)
Cohort 2 (233 women
with FSD)
p-Value
Age (years) 20.0 [17.8–25.0] 48.0 [36.0–56.0] <0.0001
BMI (kg/m2) 23.7 [21.0–29.0] 24.4 [21.4–29.0] 0.462
Waist circumference (cm) 85.0 [74.0–99.3] 92.0 [84.0–103.2] 0.001
FPG (mg/dl) 85.5 [81.0–91.3] 90.0 [83.8–98.0] 0.001
Insulin (mU/L) 10.0 [6.2-15.5] 7.5 [5.2–14.2] 0.121
Glycated Hemoglobin (mmol/mol) 33.0 [31.0–35.0] 37.0 [34.0–41.0] <0.001
HOMA IR 2.2 [1.3–3.3] 1.6 [1.1–3.3] 0.149
Total cholesterol (mg/dl) 166.9 ± 30.1 203.2 ± 41.1 <0.0001
HDL cholesterol (mg/dl) 56.8 ± 13.2 61.6 ± 16.0 0.036
Triglycerides (mg/dl) 72.0 [52.8–93.0] 79.0 [56–119.5] 0.088
LDL cholesterol (mg/dl) 89.5 [69.0–116.3] 119.0 [99.0–144] <0.001
SBP (mm Hg) 113.5 [100.0–120.0] 120.0 [110.0–130.0] <0.0001
DBP (mm Hg) 70.0 [63.8–80.0] 75.0 [70.0–80.0] 0.041
FM (kg) 15.7 [10.6–24.2] 18.9 [14.9–27.5] 0.125
FFM (kg) 47.3 [45.2–51.1] 43.1 [41.7–45.8] <0.0001
PCOS (%) 83.3 [n = 55] — —
Not PCOS (%) 13.6 [n = 9] — —
Patients without definitive diagnosis of PCOS (%) 3.0 [n = 2] — —
Physical activity (%) 48.5 [n = 32] 30.5 [n = 71] 0.060
Menopause (%) — 46.8 [109]
Sexually active (%) 54.5 [n = 36] — —
Smoking habit (%) 6.1 [n = 4] 21.0 [n = 49] 0.467
ESR (mm/h) 16.0 [6.0–25.5] — —
Uric acid (mg/dl) 4.5 ± 1.0 — —
CRP (mg/dl) 0.4 [0.1–0.9] — —
Ferritin (ng/ml) 30.0 [16.5–47.5] — —
WBC (mm3) 6.8 ± 2.1 — —
LH (U/L) 7.3 [4.0–12.1] 11.5 [5.3–30.4] <0.0001
FSH (U/L) 5.4 [4.3–6.4] 18.4 [7.0–70.2] <0.0001
Estradiol (pg/ml) 38.5 [26.8–59.3] 28.0 [13.6–52.0] 0.035
Prolactin (ng/ml) 14.6 [8.8–17.8] 9.2 [7.2–15.3] 0.001
Testosterone (nmol/L) 1.5 [1.0–2.2] 0.8 [0.5–1.4] <0.0001
SHBG (nmol/L) 36.1 [27.4–62.7] 58.7 [41.2–82.8] <0.0001
FAI 3.6 [1.9–7.0] 1.5 [0.8–2.5] <0.0001
Androstenedione nmol/L) 7.6 [5.4–11.8] 4.4 [2.5–6.5] <0.0001
DHEAS (µmol/L) 6.4 [4.9–8.2] 2.8 [1.6–4.4] <0.0001
AMH (ng/ml) 7.0 [4.4–10.2] 0.2 [0.1–2.4] <0.0001March 2021 | Volume 12 | ArticleData are expressed as mean ± SD when normally distributed, median (quartile) when not normally distributed, and percentage when categorical.
Differences in not normally distributed continuous variables were assessed by Mann–Whitney U test for comparison between the two groups. Differences in normally distributed continuous
variables were assessed by unpaired T test. Differences in categorical variables were assessed by Chi squared test.
BMI, Body Mass Index; FPG, Fasting Plasma Glucose; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; PCOS, Polycystic Ovary Syndrome; ESR, Erythrocyte Sedimentation
Rate; CRP, C-Reactive Protein; WBC, White Blood Cells; LH, Luteinizing Hormone; FSH, Follicle Stimulating Hormone; SHBG, Sex Hormone Binding Globulin; FAI, Free Androgen Index;
DHEAS, Dehydro-epiandrosterone Sulfate; AMH, Anti Mullerian Hormone.
The bold values are statistically significant values.641446
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SHBG threshold of 33.4 nmol/L as the most appropriate to
discriminate women with pathologic NAFLD-LFS.
In the first study cohort, including women with
oligomenorrhea and/or hirsutism and enriched in PCOS
patients, the assessment of metabolic parameters confirmed
that SHBG <33.4 nmol/L identifies patients with adverse
metabolic profile, including worse blood pressure, BMI, waist
circumference, body composition (increased fat mass and
reduced fat free mass), insulin, triglycerides and HDL cholesterol.
In order to confirm the reliability of SHBG <33.4 nmol/L as a
marker of metabolic impairment and increased NAFLD risk, a
second larger independent cohort of women with sexual
dysfunction was analyzed. Also in this population, SHBG
values lower than 33.4 nmol/l allowed to identify women with
higher BMI and waist circumference, worse glyco-lipid profile
and, notably, pathological NAFLD-LFS values. Furthermore, in
this population, SHBG values lower than 33.4 nmol/l,
independently of age, menopausal status and years sinceFrontiers in Endocrinology | www.frontiersin.org 6menopause, also identified patients with a numerical higher
clitoral PI. This is in line with recent findings, which showed
that, in women consulting for sexual dysfunction, the clitoral PI,
an index of vascular resistance, is higher in patients with
metabolic impairments (59–61).
Hence, SHBG <33.4 nmol/L is an effective marker for
identifying women with altered metabolic parameters and
higher NAFLD risk in either high risk groups, such as those
with PCOS, or those consulting for conditions not directly linked
to metabolic disease, such as female sexual dysfunction.
The role of SHBG as a marker of metabolic alterations is not
completely understood. Some preclinical studies have been
aimed at investigating whether reduced SHBG is a cause or a
consequence of the metabolic dysregulation. Overexpression of
SHBG, by creating a double transgenic mouse (SHBG-C57BL/
ksJ-db/db), in a NAFLD model or in a diet–induced model of
hepatic steatosis, significantly reduced liver fat accumulation
through PPARg modulation (62). On the contrary, an




Age (years) 66 0.133 0.288
BMI (kg/m2) 64 0.657 <0.0001
Waist circumference (cm) 55 0.598 <0.0001
FPG (mg/dl) 66 0.427 <0.0001
Insulin (mu/L) 66 0.850 <0.0001
Glycated hemoglobin (mmol/mol) 57 0.275 0.035
HOMA IR 59 0.867 <0.0001
Total cholesterol (mg/dl) 66 0.037 0.768
HDL cholesterol (mg/dl) 66 −0.286 0.022
Triglycerides (mg/dl) 66 0.333 0.006
LDL cholesterol (mg/dl) 61 −0.029 0.822
SBP (mm Hg) 66 0.404 0.001
DBP (mm Hg) 66 0.473 <0.0001
FM (kg) 42 0.579 <0.0001
FFM (kg) 42 0.260 0.097
Physical activity 65 −0.271 0.029
Hours of physical activity/week 65 −0.287 0.020
ESR (mm/h) 49 0.527 <0.0001
Uric acid (mg/dl) 45 0.180 0.237
CRP (mg/dl) 47 0.375 0.009
Ferritin (ng/ml) 53 0.236 0.088
WBC (mm3) 59 0.317 0.014
LH (U/L) 65 0.195 0.120
FSH (U/L) 65 0.066 0.601
Estradiol (pg/ml) 54 0.033 0.815
Prolactin (ng/ml) 62 0.168 0.192
Testosterone (nmol/L) 63 0.127 0.320
SHBG (nmol/L) 56 −0.557 <0.0001
FAI 55 0.487 <0.0001
Androstenedione (nmol/L) 60 0.224 0.085
DHEAS (µmol/L) 62 −0.188 0.142
AMH (ng/ml) 59 −0.162 0.220March 2021 | Volume 12 | Arti*Unadjusted correlation coefficients (r) and levels of significance (P) were derived from Spearman analysis.
BMI, Body Mass Index; FPG, Fasting Plasma Glucose; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; FM, Fat Mass; FFM, Free Fat Mass; ESR, Erythrocyte Sedimentation
Rate; CRP, C-Reactive Protein; WBC, White Blood Cells; LH, Luteinizing Hormone; FSH, Follicle Stimulating Hormone; SHBG, Sex Hormone Binding Globulin; FAI, Free Androgen Index;
DHEAS, Dehydro-epiandrosterone Sulfate; AMH, Anti Mullerian Hormone.
The bold values are statistically significant values.cle 641446
Di Stasi et al. SHBG predicts NAFLD in Womensecretion downregulates SHBG production (63). These data
provide potential mechanisms by which SHBG may be either a
cause or a consequence of NAFLD onset and progression (57).
Clinical data also support a putative causal role of SHBG towards
the development of NAFLD. In fact, in a recent study in a cohort
of 3389 Chinese patients, lower baseline SHBG was associated
with a higher occurrence of NAFLD, during a 3-year follow-up,
and, conversely, higher SHBG at study entry predicted a more
frequent recovery from NAFLD (64). However, due to the sex
steroid-dependence of SHBG, its own role in describing the
metabolic status is largely unclear. In men, it has been recently
shown that SHBG, independently of T, is associated with worse
lipid profile and blood pressure (65), thus supporting the value of
SHBG as a pure marker of metabolic disorders. In women,
increased testosterone levels are associated with lower SHBG,
as well as with dyslipidemia and insulin resistance (66, 67).
Indeed, this complicates the interpretation of lower SHBG levels.
Interestingly, in both the experimental cohorts evaluated in the
present study, SHBG below 33.4 nmol/L did not identify women
with increased androgen levels, thus excluding that these
hormones participate in worse metabolic pattern associated
with low SHBG, at least when this threshold is used.
The relevance of our results relies on the recognition of SHBG
as a single, and easy-to-obtain, parameter that can reliably
identify patients with more adverse metabolic parameters and,
even more importantly, establish which patients have higher
probability of having NALFD. This may simplify the every-day
clinical practice because, despite being a streamlining, the
available scores take extra time during the visit for their
calculation. For this reason, in a clinical setting, having a
single, rapid, and low cost marker, such as SHBG, can be the
first “alarm bell” to deepen liver conditions in these patients (55,
68). The confirmation of the reliability of this value as a cut-offFrontiers in Endocrinology | www.frontiersin.org 7indicative of a higher risk of NAFLD even in an independent and
population with different clinical background, strengthen the
generalizability of our results.
The systematic assessment of NAFLD risk is of pivotal
importance because NAFLD is associated with an increased
prevalence and incidence of T2DM and cardiovascular disease
(69–71). The recognition of patients that, although young or
apparently healthy, have hallmarks of NAFLD disease may help
the physician in directing the diagnostic workup and further
investigate liver disease thorough more accurate, albeit more
expensive and invasive, tests and to implement more strict
lifestyle or pharmacologic interventions.
This study has some limitations, including the small sample size
and the heterogeneity of the cohort #1, which is not purely made of
PCOS patients but it includes women with clinical features that
deserve periodic assessment for a possible development of PCOS. In
fact, it is known that subjects with even a single diagnostic factor are
at higher risk of developing PCOS as well as MetS and NAFLD (72,
73). In addition, NAFLD was not diagnosed with imaging studies
but only estimated with a clinical algorithm. Finally, in both the
cohorts, androgens were not measured by the gold-standardFIGURE 1 | Receiver operating characteristic (ROC) curve for SHBG in
detecting NAFLD risk according to NAFLD-LFS (values > -0.640 predict
NAFLD with sensitivity of 86% and specificity of 71 %) in the first cohort.FIGURE 2 | B and 95% confidence interval (CI) for several metabolic and
hormonal parameters as a function of SHBG <33.4 nmol/L as compared with
SHBG ≥33.4 nmol/L in Cohort 1. Data are expressed as number of standard
deviations from the mean value. The standardized values are based on log-
transformed parameters. The statistics based on raw data are reported in
Supplementary Table 1. SBP, systolic blood pressure; DBP, diastolic blood
pressure; BMI, body mass index; WC, waist circumference; FM, fat mass; FFM,
free fat mass; FPG, fasting blood glucose; HbA1c, glycated hemoglobin;
HOMA, Homeostatic Model Assessment for Insulin Resistance; HDL, High-
Density Lipoprotein; LDL, low-density lipoprotein; LH, Luteinizing hormone;
FSH, Follicle-stimulating hormone; FAI, Free androgen index; DHEAS,
Dehydroepiandrosterone sulfate; AMH, Anti-müllerian hormone; V, volume.March 2021 | Volume 12 | Article 641446
Di Stasi et al. SHBG predicts NAFLD in Womenmethod, i.e. mass spectrometry, although a highly reliable
immunoassay has been used.
The strength of this study is that the threshold value of SHBG
that we analytically found in this small sample replicates valuesFrontiers in Endocrinology | www.frontiersin.org 8previously identified in a larger population. In our analytical
sample, SHBG <33.4 nmol/L has good accuracy, sensitivity and
specificity, and it is capable of identifying higher risk of NAFLD,
either in a population of young women predisposed to metabolicFIGURE 4 | B and 95% confidence interval (CI) for clitoral vascular parameters as a function of SHBG<33.4 nmol/L as compared with SHBG≥33.4 nmol/L in Cohort
2. Data are expressed as number of standard deviations from the mean value. Black diamonds: unadjusted data; white diamonds: data adjusted for age,
menopausal status and years from menopause. PI, pulsatility index; PSV, peak systolic velocity; ACC, basal acceleration.FIGURE 3 | B and 95% confidence interval (CI) for several metabolic and hormonal parameters as a function of SHBG <33.4 nmol/L as compared with SHBG
≥33.4 nmol/L in Cohort 2. Data are expressed as number of standard deviations from the mean value. The standardized values are based on log-transformed
parameters. The statistics based on raw data are reported in Supplementary Table 2. Black diamonds: unadjusted data; white diamonds: data adjusted for age
and waist circumference. SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WC, waist circumference; FM, fat mass; FFM, free fat
mass; FPG, fasting blood glucose; HbA1c, glycated hemoglobin; HOMA, Homeostatic Model Assessment for Insulin Resistance; HDL, High-Density Lipoprotein;
LDL, low-density lipoprotein; LH, Luteinizing hormone; FSH, Follicle-stimulating hormone; FAI, Free androgen index; DHEAS, Dehydroepiandrosterone sulfate; AMH,
Anti-müllerian hormone; V, volume.March 2021 | Volume 12 | Article 641446
Di Stasi et al. SHBG predicts NAFLD in Womenimpairment or in young-adult/middle-aged women consulting
for female sexual dysfunction.
A future perspective will be to evaluate whether treating
NAFLD with lifestyle interventions (nutrition and physical
activity) or with medications has consequences on SHBG
values, thus confirming its role as a marker of liver health.
In conclusion, this study provides a new evidence in the
complex diagnostic process of NAFLD in patients at a higher
risk, which can be used as a first test to calibrate a subsequent
targeted diagnostic assessment.DATA AVAILABILITY STATEMENT
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